But this comes in second-line breast cancer, a use the group isn’t pursuing.
ApexOnco Front Page
Recent articles
The company admits defeat with zelenectide.
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
No fewer than four ADCs with this target start human testing.
On a cross-trial basis varegacestat beats Ogsiveo.
The group will start a pivotal trial of samuraciclib following promising second-line results.
